65,437 trials
ST Segment Elevation Acute Myocardial Infarction
Primary: Difference Between the Anakinra Arm and Placebo Arm in Change in End-systolic Volume Indices From Baseline to Follow up Exam 10-14 Weeks Later at Cardiac Magnetic…
Plaque Psoriasis
Primary: Number of Patients From Group B Who Achieve a Physician's Global Assessment (PGA) of Clear or Almost Clear at Week 12. — 11 Participants
Non-small Cell Lung Cancer
Primary: Overall Survival — 8.5; 9.2 Months
Hereditary Angioedema
Primary: Time to Start of Relief of Symptoms From HAE Attack — 1.17; 0.5; 1.5 Hours — p=0.0025
Type 2 Diabetes Mellitus
Primary: Change in Glycosylated Hemoglobin (HbA1c) — -1.00; -1.14 Percentage of glycosylated hemoglobin — p=0.055
Aortic Aneurysm, Abdominal
Primary: Number of Subjects With Aneurysm Volume Increase Greater Than 10% at 2 Years Post-procedure — 9; 31 participants — p=<0.001
Low Back Pain
Primary: Difference in Number of Magnetic Resonance Imaging (MRI)-Positive Discs Diagnosed Positive by Provocative Discography (PD) and Functional Anesthetic Discography (F.A.D.)…
Actinic Keratosis
Primary: Change From Baseline in Percentage of Lesion Count — -43.3; -77.4 percentage of lesion count
Infections, Papillomavirus
Primary: Number of Subjects Seroprotected Against Diphtheria and Tetanus — 238; 233; 240; 233 Participants
Pediatric Heterozygous Hypercholesterolemia
Primary: Parent-metabolite Population Pharmacokinetic (PK) Model for Atorvastatin and Its Metabolites: Atorvastatin Apparent Clearance (CL/F) — 553; 543 L/hr
Gastric Ulcer
Primary: Number of Subjects Monitored for Long-term Safety of PN 400 — 239 participants
Infections, Bacterial
Primary: Plasma Retapumulin Pharmacokinetic Parameters by Treatment at Days 1 and 3 Evaluated by Plasma AUC After Dosing — 0.8663; 0.3816; 4.2802; 2.0881 ng.h /mL
HIV Infections
Primary: Time-weighted Average Change From Baseline Through Week 24 (DAVG24) in Plasma HIV-1 RNA — -1.580; -1.549 log10 copies/mL — p=0.55
Heart Failure, Congestive
Primary: Number of Participants With Adverse Events by Severity From Week 0 Through Week 8 (CRV-IR) or Week 14 (SK&F-105517-D) — 0; 1; 2; 5 participants
Human Immunodeficiency Viruses
Primary: Architect HIV Combo Test Data for Clinical Specificity in Population at Low Risk for HIV Infection — 37; 14; 0; 6113 Blood Specimens